In Zimbabwe, health authorities have begun distributing lenacapavir, a long-acting HIV prevention injectable that is administered just twice a year. This marks a major advancement in HIV prevention strategy for high-risk populations, including sex workers and young women groups disproportionately affected by new infections.
Developed by Gilead Sciences and supported by global funding partners, lenacapavir offers significantly improved adherence compared to daily oral alternatives. Advocates say its discreet and infrequent dosing makes it more user-friendly and reduces stigma associated with daily medication routines.
Initial rollout plans aim to reach approximately 46,000 people, with potential expansion depending on funding and infrastructure capacity. While donor funding remains a challenge across Africa, health experts note that scalable prevention tools like this could reshape continent-wide HIV response strategies.
Critics emphasize that lenacapavir should be part of a comprehensive prevention package including condoms, education, and broader health system strengthening to maximize its public health impact. Nevertheless, its approval is viewed as a breakthrough in HIV prevention innovation.